(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute myeloid leukemia have been published in the peer-reviewed journal Leukemia. The publication highlights data including long-term survival outcomes from two-year follow-up and better outcomes in high-risk patients. 18.4 month median Overall Survival was observed in patients who received 1 or 2 lines of prior therapy. 52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy.
Sandesh Seth, Actinium's CEO, said, "Over the course of 2025, we expect to generate additional clinical data further supporting Actimab-A's mutation agnostic, backbone therapy potential for radiation sensitive myeloid malignancies."
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Q4%20FFO%20and%20Revenues%20Top%20Estimates%20%7C%20Nasdaq&_biz_n=9&rnd=928424&cdn_o=a&_biz_z=1743109483464)
